Geoff Rickly’s Collect Records Is Looking For New Investors, If You’re Interested

In an extremely weird juxtaposition between internet outrage, capitalism, and awesome independent music, Geoff Rickly’s Brooklyn-based label, Collect Records, recently cut ties with their major investor Martin Shkreli. When The New York Times reported that Shrekli’s company, Turing Pharmaceuticals, was responsible for a 5000% increase on a drug called Daraprim, commonly used to treat AIDS and cancer patients, and his connection to Collect Records was revealed, major backlash ensued, particularly from the bands signed to the label. (It should be noted that a bunch of other vile behavior from Shkreli was uncovered in the process).

So Rickly is looking to pick up the pieces for his excellent label, but it’s a weird situation. Even though Shkreli rescinded the drug price increase after intense public outcry, he’s still not a figure most bands on the roster are probably comfortable being associated with. And as Rickly told Noisey, Shkreli was essentially an angel investor in Collect Records who gave the label a blank check. It’s unlikely he’ll find a situation like that again.

Since the company is rescinding the price increase patients probably haven’t faced monumental financial strain after all? Anyway, Rickly emphasizes that his focus will be on the bands and running an ethical business:

And–obviously– my first duty is to my bands and artists. To make them feel comfortable about being on an ethically responsible label. xx

Are you one of the random millionaires that lives in Brooklyn? Why not consider investing in Collect Records? The No Devotion record is honestly one of the year’s best releases. Listen here if you haven’t heard it yet.